Alaunos Therapeutics (TCRT) Competitors

$2.62 -0.05 (-1.87%)

As of 01:20 PM Eastern

TCRT vs. MRKR, VTGN, AEON, CPHI, and LTRN

Should you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Marker Therapeutics (MRKR), VistaGen Therapeutics (VTGN), AEON Biopharma (AEON), China Pharma (CPHI), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry.

How does Alaunos Therapeutics compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Marker Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500.

Marker Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.85	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.21	N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Alaunos Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -80.86% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-80.86%	-67.04%
Alaunos Therapeutics	N/A	-172.65%	-123.32%

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 593.96%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Alaunos Therapeutics	Neutral

Summary

Marker Therapeutics beats Alaunos Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to VistaGen Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Alaunos Therapeutics has higher earnings, but lower revenue than VistaGen Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.21	N/A
VistaGen Therapeutics	$789K	31.28	-$51.42M	-$1.89	N/A

Alaunos Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

VistaGen Therapeutics' return on equity of -109.72% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-172.65%	-123.32%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.00 equaled VistaGen Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 52.49%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

VistaGen Therapeutics beats Alaunos Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Alaunos Therapeutics compare to AEON Biopharma?

Alaunos Therapeutics (NASDAQ:TCRT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.21	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Alaunos Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

AEON Biopharma's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-172.65%	-123.32%
AEON Biopharma	N/A	N/A	-994.63%

In the previous week, Alaunos Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for AEON Biopharma. Alaunos Therapeutics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
AEON Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 0.9% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Alaunos Therapeutics and AEON Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Alaunos Therapeutics compare to China Pharma?

Alaunos Therapeutics (NASDAQ:TCRT) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alaunos Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

27.7% of Alaunos Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 6.4% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

China Pharma has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.21	N/A
China Pharma	$4.14M	5.20	-$3.08M	-$0.75	N/A

Alaunos Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-172.65%	-123.32%
China Pharma	-85.56%	-63.93%	-31.42%

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

China Pharma beats Alaunos Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lantern Pharma has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lantern Pharma is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.57	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.21	N/A

Lantern Pharma's return on equity of -150.76% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-150.76%	-108.38%
Alaunos Therapeutics	N/A	-172.65%	-123.32%

In the previous week, Lantern Pharma had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Lantern Pharma and 1 mentions for Alaunos Therapeutics. Lantern Pharma's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantern Pharma beats Alaunos Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRT vs. The Competition

Export

Metric	Alaunos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.29M	$3.05B	$6.19B	$12.25B
Dividend Yield	N/A	1.88%	2.78%	5.24%
P/E Ratio	-1.19	17.52	28.68	27.24
Price / Sales	N/A	285.40	534.15	76.05
Price / Cash	N/A	56.30	43.30	53.97
Price / Book	2.82	4.27	9.97	6.81
Net Income	-$4.18M	$72.19M	$3.54B	$333.00M
7 Day Performance	N/A	N/A	N/A	0.16%
1 Month Performance	-9.97%	3.68%	4.50%	7.10%
1 Year Performance	-12.96%	45.34%	40.23%	40.26%

Alaunos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRT Alaunos Therapeutics	0.5433 of 5 stars	$2.62 -1.9%	N/A	-8.0%	$6.29M	N/A	N/A	40	Upcoming Earnings
MRKR Marker Therapeutics	1.9423 of 5 stars	$1.46 +0.7%	$10.00 +584.9%	+29.7%	$24.18M	$3.55M	N/A	60	Gap Up
VTGN VistaGen Therapeutics	1.8214 of 5 stars	$0.61 +2.9%	$0.95 +54.9%	-72.8%	$23.61M	$490K	N/A	40	News Coverage
AEON AEON Biopharma	0.8098 of 5 stars	$0.92 -4.2%	N/A	+89.8%	$23.15M	N/A	5.08	5
CPHI China Pharma	N/A	$0.55 +0.0%	N/A	-71.9%	$22.29M	$4.14M	N/A	250	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. MRKR, VTGN, AEON, CPHI, and LTRN

How does Alaunos Therapeutics compare to Marker Therapeutics?

Summary

How does Alaunos Therapeutics compare to VistaGen Therapeutics?

Summary

How does Alaunos Therapeutics compare to AEON Biopharma?

Summary

How does Alaunos Therapeutics compare to China Pharma?

Summary

How does Alaunos Therapeutics compare to Lantern Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. MRKR, VTGN, AEON, CPHI, and LTRN

How does Alaunos Therapeutics compare to Marker Therapeutics?

Which has more risk & volatility, MRKR or TCRT?

Which has higher valuation and earnings, MRKR or TCRT?

Do institutionals and insiders believe in MRKR or TCRT?

Is MRKR or TCRT more profitable?

Do analysts recommend MRKR or TCRT?

Does the media favor MRKR or TCRT?

Summary

How does Alaunos Therapeutics compare to VistaGen Therapeutics?

Which has stronger earnings and valuation, TCRT or VTGN?

Which has more volatility and risk, TCRT or VTGN?

Is TCRT or VTGN more profitable?

Does the media refer more to TCRT or VTGN?

Do analysts rate TCRT or VTGN?

Do institutionals & insiders believe in TCRT or VTGN?

Summary

How does Alaunos Therapeutics compare to AEON Biopharma?

Which has stronger earnings and valuation, TCRT or AEON?

Which has more volatility and risk, TCRT or AEON?

Is TCRT or AEON more profitable?

Does the media refer more to TCRT or AEON?

Do analysts rate TCRT or AEON?

Do institutionals & insiders believe in TCRT or AEON?

Summary

How does Alaunos Therapeutics compare to China Pharma?

Do analysts rate TCRT or CPHI?

Which has more volatility and risk, TCRT or CPHI?

Do institutionals & insiders believe in TCRT or CPHI?

Which has stronger earnings and valuation, TCRT or CPHI?

Is TCRT or CPHI more profitable?

Does the media refer more to TCRT or CPHI?

Summary

How does Alaunos Therapeutics compare to Lantern Pharma?

Do analysts recommend LTRN or TCRT?

Which has more risk and volatility, LTRN or TCRT?

Do insiders and institutionals believe in LTRN or TCRT?

Which has higher valuation & earnings, LTRN or TCRT?

Is LTRN or TCRT more profitable?

Does the media prefer LTRN or TCRT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools